Results 111 to 120 of about 211,160 (222)

Uterine sarcoma: the possibility of modeling a rare tumor and providing its morphological description

Исследования и практика в медицине
Purpose of the study. To create a model of uterine sarcoma in female white mongrel rats and provide description of its morphological features.Materials and methods.
E. M. Frantsiyants, A. I. Shikhlyarova, I. V. Neskubina, I. V. Kaplieva, L. K. Trepitaki, V. A. Bandovkina, Yu. A. Pogorelova, E. I. Surikova, T. I. Moiseenko, N. D. Cheryarina, E. R. Tolmakh, A. A. Vereskunova, O. G. Ishonina, E. V. Verenikina, A. P. Menshenina   +14 more
doaj   +1 more source

High-grade uterine sarcoma with BCOR internal tandem duplication presenting with total uterine inversion.

, 2020
Casestudy: High-grade uterine sarcomas are rare mesenchymal tumors in which the underlying genetics of many have been recently elucidated. BCOR internal tandem duplications are present in a subset of high-grade uterine sarcomas.
Greenwell, T J, Kumar, S, Hysell, C
core   +1 more source

Neutrophil to lymphocyte ratio as an assessment tool to differentiate between uterine sarcoma and myoma: a systematic review and meta-analysis

BMC Cancer
Background This systematic review and meta-analysis aimed to determine the potential value of neutrophil to lymphocyte ratio (NLR) as an assessment tool in the clinical distinction between uterine sarcoma and uterine leiomyoma. Methods We comprehensively
Fatemeh Tabatabaei, Saghar Babadi, Shima Nourigheimasi, Arshin Ghaedi, Monireh Khanzadeh, Aida Bazrgar, Morad Kohandel Gargari, Shokoufeh Khanzadeh   +7 more
doaj   +1 more source

Uterine sarcoma: twenty-seven years of experience

, 2003
PURPOSE: A correlation of treatment for uterine sarcoma with outcome, prognostic importance of pathology, and clinical parameters. PATIENTS AND METHODS: One hundred forty-one patients (median age: 56 years, range: 19-85 years) with a histologically ...
Meldolesi, E, Galardi, A, Scoccianti, S, Piperno, G, Villanucci, A, Blake, P, Judson, I, Lodge, N, Simontacchi, G, Biti, G. P, Harmer, C., Shah, N, PAIAR, FABIOLA, Livi, L, Amunni, G, Barca, R   +15 more
core  

Histopathology of Endometrial Stromal Sarcoma with Emphasis on Immunohistochemistry Marker Expression: Report of Three Cases

Medical Journal of Dr. D.Y. Patil Vidyapeeth
Endometrial stromal tumors are rare uterine mesenchymal neoplasms. Endometrial stromal sarcomas (ESSs) are of endometrial stromal origin that accounts for approximately 1% of all uterine malignant neoplasms.
Narayanamoorthy Keerthyraj, Vigneswaramoorthi Vinayagamoorthi, Erli Amel Ivan, V Sriram, Govindasamy Revathi, Ramya Gandhi   +5 more
doaj   +1 more source

Aggressive Kaposi's Sarcoma in a 6-month-old African infant: Case Report and Review of the Literature. [PDF]

, 2000
Kaposi's sarcoma (KS), known to exist in Africa for a century now, was rare in children and unknown in the newborn. With the onset of the HIV/AIDS epidemic, a more aggressive, disseminated type of KS (AKS) was recognized. Recently KS was diagnosed in a 6-
Maduhu, I Z, Manji, K P, Amir, H
core  

Uterine Sarcomas

Surgical Oncology Clinics of North America
Uterine sarcomas are very infrequent and heterogeneous entities. Due to its rarity, pathological diagnosis, surgical management, and systemic treatment are challenging. Treatment decision process in these tumors should be taken in a multidisciplinary tumor board.
Monica Avila, Mitchel S. Hoffman
openaire   +3 more sources

Evaluation of surgical approach and adjuvant therapy in uterine sarcomas: an 11-year population-based study

BMC Cancer
Background Uterine sarcomas are rare and high-quality evidence regarding optimal treatment is limited and difficult to produce. Methods A total of 618 patients with uterine sarcoma were identified in the Swedish Quality Registry for Gynecologic Cancer ...
Filip Herbst, Erik Holmberg, Louise Moberg, Christer Borgfeldt   +3 more
doaj   +1 more source

Uterine sarcoma

Hematology/Oncology and Stem Cell Therapy, 2011
Korshid, Ezzeldin, Al-Badawi, Ismail A.
openaire   +1 more source

Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study

, 2019
Purpose: Uterine sarcoma accounts for 3-9% of uterine malignant tumors and has poor prognosis. Pazopanib is an oral multi-kinase inhibitor and the only tyrosine kinase inhibitor which has been approved for metastatic soft tissue sarcoma.
Ates, Ozturk, Oksuzoglu, Berna, Yilmaz, Munevver, Guven, Deniz Can, ARIK, ZAFER, Meydanli, Mehmet Mutlu, Sunar, Veli, Korkmaz, Vakkas, AKIN, SERKAN   +8 more
core